Jim Barlow

Jim Barlow became the CEO of ImmunoGenesis in April 2020. Prior to joining ImmunoGenesis, Jim was Vice President of Operations and Business Development for Geneos Therapeutics. Jim played an integral role in the company formation of Geneos, a personalized neoantigen-targeting cancer vaccine company that is a spin-off from Inovio Pharmaceuticals. Jim was one of 2 initial employees, helped build-out the management team and established all key operational aspects of the company. He also led the tumor prioritization efforts resulting in the design and initiation of the company’s first clinical trial less than 9 months after obtaining Series A financing.

Before joining Geneos, Jim drove the development of Inovio’s Immuno-Oncology (IO) product strategy. In this effort, he led a cross-functional team across Commercial, Clinical, Product Development, R&D and Business Development to establish a set of key strategic principles. Jim drove the product prioritization efforts based on these principles, established the IO Advisory Panel, and drove KOL and pharma partner interactions to position the company to embark on major clinical programs across four tumor types of interest. These programs are evaluating combination regimens of Inovio’s cancer immunotherapies with PD-(L)1 inhibitors from 3 different pharma partners – Jim drove the establishment of two of these three partnerships as well as a clinical partnership with the Parker Institute for Cancer Immunotherapy.

Prior to Inovio, Jim was at Bristol-Myers Squibb where he was the Payer Marketing Lead for YERVOY®, the pioneering cancer immunotherapy whose approval set off the current wave of immunotherapy development in Oncology. Given the “First in Class” nature of the product and premium price associated with it, Jim created a number of innovative programs to optimize market access. While at BMS, Jim also worked on the overall IO franchise commercial strategy including the development of communication planning for the groundbreaking immunotherapy, OPDIVO®. Prior to BMS, Jim spent 8 years at Merck working in commercial leadership roles with increasing responsibility for the Oncology franchise.

Jim received a MBA (strategy and marketing) with honors from the Tepper School of Business at Carnegie Mellon University. He was awarded the Dean’s Scholarship from Tepper. Jim received his Bachelor of Arts in Math and Economics from Colgate University where he was awarded the Alumni Memorial Scholarship and he graduated Summa Cum Laude.